223 related articles for article (PubMed ID: 38287066)
1. Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs.
Abd El-Hafeez T; Shams MY; Elshaier YAMM; Farghaly HM; Hassanien AE
Sci Rep; 2024 Jan; 14(1):2428. PubMed ID: 38287066
[TBL] [Abstract][Full Text] [Related]
2. An integrated framework for identification of effective and synergistic anti-cancer drug combinations.
Sharma A; Rani R
J Bioinform Comput Biol; 2018 Oct; 16(5):1850017. PubMed ID: 30304987
[TBL] [Abstract][Full Text] [Related]
3. A novel approach to predicting the synergy of anti-cancer drug combinations using document-based feature extraction.
Shim Y; Lee M; Kim PJ; Kim HG
BMC Bioinformatics; 2022 May; 23(1):163. PubMed ID: 35513784
[TBL] [Abstract][Full Text] [Related]
4. In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data.
Celebi R; Bear Don't Walk O; Movva R; Alpsoy S; Dumontier M
Sci Rep; 2019 Jun; 9(1):8949. PubMed ID: 31222109
[TBL] [Abstract][Full Text] [Related]
5. In silico drug combination discovery for personalized cancer therapy.
Jeon M; Kim S; Park S; Lee H; Kang J
BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
[TBL] [Abstract][Full Text] [Related]
6. Mind the Curve: Dose-Response Fitting Biases the Synergy Scores across Software Used for Chemotherapy Combination Studies.
Fuentealba-Manosalva O; Mansilla M; Buelvas N; Martin-Martin A; Torres CG; López-Muñoz RA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298656
[TBL] [Abstract][Full Text] [Related]
7. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs.
Teicher BA
Curr Opin Pharmacol; 2010 Aug; 10(4):397-404. PubMed ID: 20547104
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer.
Saputra EC; Huang L; Chen Y; Tucker-Kellogg L
Cancer Res; 2018 May; 78(9):2419-2431. PubMed ID: 29686021
[TBL] [Abstract][Full Text] [Related]
9. Effective drug combinations in breast, colon and pancreatic cancer cells.
Jaaks P; Coker EA; Vis DJ; Edwards O; Carpenter EF; Leto SM; Dwane L; Sassi F; Lightfoot H; Barthorpe S; van der Meer D; Yang W; Beck A; Mironenko T; Hall C; Hall J; Mali I; Richardson L; Tolley C; Morris J; Thomas F; Lleshi E; Aben N; Benes CH; Bertotti A; Trusolino L; Wessels L; Garnett MJ
Nature; 2022 Mar; 603(7899):166-173. PubMed ID: 35197630
[TBL] [Abstract][Full Text] [Related]
10. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Friedman AA; Amzallag A; Pruteanu-Malinici I; Baniya S; Cooper ZA; Piris A; Hargreaves L; Igras V; Frederick DT; Lawrence DP; Haber DA; Flaherty KT; Wargo JA; Ramaswamy S; Benes CH; Fisher DE
PLoS One; 2015; 10(10):e0140310. PubMed ID: 26461489
[TBL] [Abstract][Full Text] [Related]
11. H-RACS: a handy tool to rank anti-cancer synergistic drugs.
Yan X; Yang Y; Chen Z; Yin Z; Deng Z; Qiu T; Tang K; Cao Z
Aging (Albany NY); 2020 Nov; 12(21):21504-21517. PubMed ID: 33173014
[TBL] [Abstract][Full Text] [Related]
12. DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy.
Liu H; Zhang W; Zou B; Wang J; Deng Y; Deng L
Nucleic Acids Res; 2020 Jan; 48(D1):D871-D881. PubMed ID: 31665429
[TBL] [Abstract][Full Text] [Related]
13. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
Budman DR; Calabro A; Kreis W
Anticancer Drugs; 2002 Nov; 13(10):1011-6. PubMed ID: 12439335
[TBL] [Abstract][Full Text] [Related]
14. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
[TBL] [Abstract][Full Text] [Related]
15. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Chou TC; Motzer RJ; Tong Y; Bosl GJ
J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
[TBL] [Abstract][Full Text] [Related]
16. Additivity predicts the efficacy of most approved combination therapies for advanced cancer.
Hwangbo H; Patterson SC; Dai A; Plana D; Palmer AC
Nat Cancer; 2023 Dec; 4(12):1693-1704. PubMed ID: 37974028
[TBL] [Abstract][Full Text] [Related]
17. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
[TBL] [Abstract][Full Text] [Related]
18. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
Menden MP; Wang D; Mason MJ; Szalai B; Bulusu KC; Guan Y; Yu T; Kang J; Jeon M; Wolfinger R; Nguyen T; Zaslavskiy M; ; Jang IS; Ghazoui Z; Ahsen ME; Vogel R; Neto EC; Norman T; Tang EKY; Garnett MJ; Veroli GYD; Fawell S; Stolovitzky G; Guinney J; Dry JR; Saez-Rodriguez J
Nat Commun; 2019 Jun; 10(1):2674. PubMed ID: 31209238
[TBL] [Abstract][Full Text] [Related]
19. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
20. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.
Smith KS; Folz BA; Adams EG; Bhuyan BK
Cancer Chemother Pharmacol; 1995; 35(6):471-82. PubMed ID: 7533669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
